CHELMSFORD, Mass., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Brooks Automation, Inc. (Nasdaq:BRKS), a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets, including semiconductor manufacturing and life sciences, today reported financial results for the third quarter and nine months ended June 30, 2013.
Fiscal Third Quarter of 2013 Financial and Operational Highlights:
- Revenues were $118.1 Million; Order Bookings increased $6.8 million on a sequential basis to $128.1 million;
- Brooks Life Science Systems Bookings increased to $18.5 million;
- GAAP Earnings Per Share was $0.02; Adjusted Earnings Per Share excluding special charges was $0.03
- Cash flow from Operations was $12.9 million;
- Cash, Cash Equivalents and Marketable Securities as of June 30, 2013 were $150.7 million, or $2.26 per diluted share with no Debt;
- Generated 17 Design-in-Wins for Semiconductor and Adjacent market customers.
|Summary of GAAP and Non-GAAP Earnings|
|Quarter Ended||Nine Months Ended|
|June 30,||March 31,||June 30,||June 30,||June 30,|
|000's except EPS||2013||2013||2012||2013||2012|
|GAAP Net Income (Loss) attributable to Brooks||$1,544||$(538)||$8,028||$(8,230)||$20,572|
|GAAP Diluted Earnings (Loss) per share||$0.02||$(0.01)||$0.12||$(0.13)||$0.31|
|Adjusted Net Income (Loss) attributable to Brooks||$1,965||$600||$8,943||$(1,277)||$25,810|
|Adjusted Diluted Earnings (Loss) per Share||$0.03||$0.01||$0.14||$(0.02)||$0.39|
A reconciliation of non-GAAP measures to the most nearly comparable GAAP measure follows the consolidated balance sheets, statements of operations and statements of cash flows included in this release.Management Comments "Despite flat market conditions over the quarter, we generated revenue and profits performance in line with our guidance. Cash flow generation was strong as we continued to improve gross margin and reduce inventory," said Steve Schwartz, Chief Executive Officer of Brooks. "We closed out several of the major Life Science Systems orders that were in our pipeline and we booked $18.5 million of orders in this business during the quarter. This was an important step in the recovery of this business after a period of slow spending. New leadership in the Life Science Systems business is strongly focused on working with current and prospective customers to maintain this momentum."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts